| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Prostatic Neoplasms | 328 | 2024 | 11101 | 16.910 |
Why?
|
| Acrylamide | 12 | 2018 | 59 | 2.680 |
Why?
|
| PTEN Phosphohydrolase | 15 | 2021 | 1111 | 2.500 |
Why?
|
| Prostate | 36 | 2024 | 1772 | 2.430 |
Why?
|
| Serine Endopeptidases | 14 | 2023 | 1022 | 2.390 |
Why?
|
| Vasectomy | 4 | 2021 | 51 | 2.330 |
Why?
|
| Prostate-Specific Antigen | 38 | 2024 | 2465 | 2.180 |
Why?
|
| Oncogene Proteins, Fusion | 19 | 2024 | 1605 | 2.090 |
Why?
|
| Follow-Up Studies | 117 | 2024 | 39127 | 1.820 |
Why?
|
| Sweden | 52 | 2024 | 1379 | 1.800 |
Why?
|
| Male | 404 | 2024 | 360703 | 1.740 |
Why?
|
| Diet | 33 | 2023 | 8048 | 1.720 |
Why?
|
| Twins, Dizygotic | 9 | 2019 | 236 | 1.610 |
Why?
|
| Prostatectomy | 26 | 2024 | 1825 | 1.600 |
Why?
|
| Melatonin | 5 | 2024 | 668 | 1.550 |
Why?
|
| Hydroxymethylglutaryl-CoA Reductase Inhibitors | 13 | 2024 | 3245 | 1.510 |
Why?
|
| Prospective Studies | 125 | 2024 | 54437 | 1.490 |
Why?
|
| Twins, Monozygotic | 9 | 2019 | 470 | 1.480 |
Why?
|
| Proportional Hazards Models | 60 | 2024 | 12474 | 1.360 |
Why?
|
| Risk Factors | 154 | 2024 | 74241 | 1.350 |
Why?
|
| Aged | 233 | 2024 | 169292 | 1.300 |
Why?
|
| Polymorphism, Single Nucleotide | 46 | 2024 | 15920 | 1.300 |
Why?
|
| Humans | 451 | 2024 | 761222 | 1.200 |
Why?
|
| Gene Expression Regulation, Neoplastic | 30 | 2024 | 8531 | 1.200 |
Why?
|
| Genetic Predisposition to Disease | 48 | 2024 | 17897 | 1.180 |
Why?
|
| Gene Expression Profiling | 24 | 2023 | 9417 | 1.110 |
Why?
|
| Middle Aged | 233 | 2024 | 220858 | 1.060 |
Why?
|
| Coffee | 7 | 2020 | 593 | 1.040 |
Why?
|
| Tissue Array Analysis | 8 | 2021 | 550 | 1.000 |
Why?
|
| Obesity | 18 | 2024 | 12940 | 1.000 |
Why?
|
| Antioxidants | 6 | 2017 | 1667 | 0.980 |
Why?
|
| Neoplasms | 26 | 2024 | 22142 | 0.970 |
Why?
|
| Incidence | 49 | 2024 | 21366 | 0.950 |
Why?
|
| Feeding Behavior | 15 | 2021 | 3183 | 0.940 |
Why?
|
| 5-alpha Reductase Inhibitors | 3 | 2022 | 112 | 0.940 |
Why?
|
| Aspirin | 8 | 2021 | 3129 | 0.930 |
Why?
|
| Disease Progression | 41 | 2024 | 13511 | 0.900 |
Why?
|
| Case-Control Studies | 68 | 2023 | 22174 | 0.880 |
Why?
|
| Exercise | 11 | 2023 | 5874 | 0.870 |
Why?
|
| Smoking | 20 | 2023 | 9055 | 0.860 |
Why?
|
| Insulin-Like Growth Factor I | 10 | 2023 | 1933 | 0.840 |
Why?
|
| Life Style | 13 | 2024 | 3907 | 0.820 |
Why?
|
| Vitamin D | 14 | 2024 | 3301 | 0.800 |
Why?
|
| BRCA1 Protein | 4 | 2023 | 1149 | 0.770 |
Why?
|
| Aneuploidy | 2 | 2024 | 555 | 0.750 |
Why?
|
| Diseases in Twins | 4 | 2019 | 446 | 0.750 |
Why?
|
| Diet, Vegetarian | 2 | 2022 | 180 | 0.740 |
Why?
|
| Androgen Antagonists | 11 | 2024 | 1408 | 0.730 |
Why?
|
| Iceland | 10 | 2021 | 184 | 0.720 |
Why?
|
| Neoplasms, Bone Tissue | 1 | 2020 | 7 | 0.720 |
Why?
|
| Trans-Activators | 7 | 2016 | 2846 | 0.720 |
Why?
|
| Cohort Studies | 73 | 2024 | 41496 | 0.700 |
Why?
|
| Adult | 152 | 2024 | 221120 | 0.690 |
Why?
|
| Metabolome | 6 | 2023 | 989 | 0.690 |
Why?
|
| Selenium | 4 | 2016 | 416 | 0.690 |
Why?
|
| Urinary Incontinence | 2 | 2024 | 490 | 0.680 |
Why?
|
| Endoribonucleases | 2 | 2013 | 227 | 0.680 |
Why?
|
| Social Change | 1 | 2020 | 153 | 0.670 |
Why?
|
| Pineal Gland | 2 | 2021 | 158 | 0.670 |
Why?
|
| Birth Weight | 6 | 2024 | 2104 | 0.670 |
Why?
|
| Carcinogens | 6 | 2013 | 452 | 0.650 |
Why?
|
| Hyperinsulinism | 2 | 2021 | 400 | 0.650 |
Why?
|
| Prognosis | 51 | 2024 | 29688 | 0.650 |
Why?
|
| Exercise Therapy | 5 | 2023 | 922 | 0.640 |
Why?
|
| Trichomonas vaginalis | 4 | 2018 | 70 | 0.630 |
Why?
|
| Early Detection of Cancer | 10 | 2023 | 3198 | 0.630 |
Why?
|
| Neoplasm Staging | 30 | 2021 | 11119 | 0.630 |
Why?
|
| Periodontal Diseases | 3 | 2009 | 450 | 0.630 |
Why?
|
| Fishes | 4 | 2018 | 600 | 0.620 |
Why?
|
| Aged, 80 and over | 69 | 2022 | 58952 | 0.620 |
Why?
|
| Risk Assessment | 42 | 2024 | 24022 | 0.620 |
Why?
|
| Registries | 23 | 2024 | 8246 | 0.610 |
Why?
|
| Body Fat Distribution | 1 | 2019 | 245 | 0.590 |
Why?
|
| Neovascularization, Pathologic | 8 | 2021 | 2636 | 0.590 |
Why?
|
| Odds Ratio | 26 | 2021 | 9652 | 0.590 |
Why?
|
| Immunohistochemistry | 24 | 2021 | 11067 | 0.580 |
Why?
|
| Health Personnel | 12 | 2024 | 3337 | 0.570 |
Why?
|
| Asparagus Plant | 1 | 2016 | 4 | 0.570 |
Why?
|
| Food Contamination | 2 | 2011 | 191 | 0.560 |
Why?
|
| Risk | 32 | 2021 | 9616 | 0.550 |
Why?
|
| Smad4 Protein | 2 | 2015 | 191 | 0.550 |
Why?
|
| Ejaculation | 4 | 2018 | 59 | 0.550 |
Why?
|
| Carotenoids | 3 | 2016 | 621 | 0.540 |
Why?
|
| Neoplasm Recurrence, Local | 13 | 2018 | 9278 | 0.540 |
Why?
|
| Twins | 3 | 2019 | 340 | 0.530 |
Why?
|
| Neoplasm Invasiveness | 12 | 2021 | 3590 | 0.530 |
Why?
|
| DNA Repair | 4 | 2023 | 2041 | 0.520 |
Why?
|
| Milk | 6 | 2021 | 440 | 0.520 |
Why?
|
| Trichomonas Infections | 3 | 2018 | 41 | 0.510 |
Why?
|
| Genetic Variation | 13 | 2018 | 6567 | 0.510 |
Why?
|
| Tobacco, Smokeless | 1 | 2016 | 133 | 0.510 |
Why?
|
| Survival Rate | 21 | 2024 | 12728 | 0.500 |
Why?
|
| Breast Neoplasms | 19 | 2023 | 20982 | 0.500 |
Why?
|
| Genetic Association Studies | 7 | 2021 | 2731 | 0.500 |
Why?
|
| Neoplasm Metastasis | 15 | 2020 | 4909 | 0.500 |
Why?
|
| Genotype | 26 | 2024 | 12985 | 0.500 |
Why?
|
| Gonadal Steroid Hormones | 3 | 2016 | 702 | 0.500 |
Why?
|
| Nonprescription Drugs | 1 | 2016 | 118 | 0.490 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 8 | 2023 | 415 | 0.490 |
Why?
|
| Urine | 1 | 2016 | 362 | 0.490 |
Why?
|
| Chromosomes, Human, Pair 8 | 4 | 2024 | 452 | 0.490 |
Why?
|
| Kallikreins | 4 | 2024 | 220 | 0.470 |
Why?
|
| Osteopontin | 2 | 2015 | 302 | 0.460 |
Why?
|
| Adenocarcinoma | 8 | 2020 | 6341 | 0.460 |
Why?
|
| Olfaction Disorders | 1 | 2016 | 224 | 0.460 |
Why?
|
| Cyclin D1 | 2 | 2015 | 451 | 0.460 |
Why?
|
| C-Reactive Protein | 5 | 2019 | 3821 | 0.450 |
Why?
|
| Colonic Neoplasms | 4 | 2020 | 2527 | 0.440 |
Why?
|
| Receptors, Androgen | 6 | 2018 | 1077 | 0.440 |
Why?
|
| Genome-Wide Association Study | 19 | 2024 | 12676 | 0.430 |
Why?
|
| Germ-Line Mutation | 5 | 2024 | 1852 | 0.430 |
Why?
|
| Walking | 2 | 2017 | 1194 | 0.420 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 4 | 2021 | 2270 | 0.420 |
Why?
|
| Motor Activity | 5 | 2015 | 2712 | 0.420 |
Why?
|
| Cell Cycle Proteins | 1 | 2024 | 3446 | 0.420 |
Why?
|
| Vitamin E | 2 | 2016 | 872 | 0.420 |
Why?
|
| Work Schedule Tolerance | 3 | 2016 | 553 | 0.420 |
Why?
|
| beta Carotene | 2 | 2011 | 523 | 0.420 |
Why?
|
| Antibodies, Protozoan | 2 | 2015 | 251 | 0.420 |
Why?
|
| Quality of Life | 14 | 2024 | 13367 | 0.410 |
Why?
|
| United States | 46 | 2024 | 72341 | 0.410 |
Why?
|
| Circadian Clocks | 1 | 2014 | 164 | 0.410 |
Why?
|
| Superoxide Dismutase | 1 | 2015 | 593 | 0.400 |
Why?
|
| Seafood | 2 | 2016 | 393 | 0.390 |
Why?
|
| Body Mass Index | 20 | 2022 | 12952 | 0.390 |
Why?
|
| Age Factors | 21 | 2022 | 18384 | 0.380 |
Why?
|
| Organic Anion Transporters | 3 | 2024 | 101 | 0.380 |
Why?
|
| Risk Reduction Behavior | 3 | 2012 | 1111 | 0.380 |
Why?
|
| Colorectal Neoplasms | 9 | 2019 | 6919 | 0.370 |
Why?
|
| Denmark | 7 | 2019 | 770 | 0.370 |
Why?
|
| Proto-Oncogene Proteins c-myc | 3 | 2024 | 987 | 0.370 |
Why?
|
| Body Height | 5 | 2022 | 1566 | 0.360 |
Why?
|
| Diet Records | 2 | 2009 | 427 | 0.360 |
Why?
|
| Zinc | 4 | 2022 | 672 | 0.360 |
Why?
|
| Dietary Supplements | 6 | 2024 | 3410 | 0.360 |
Why?
|
| Sex Characteristics | 2 | 2020 | 2640 | 0.360 |
Why?
|
| Time Factors | 28 | 2019 | 39957 | 0.350 |
Why?
|
| Stromal Cells | 4 | 2017 | 1329 | 0.350 |
Why?
|
| Dairy Products | 6 | 2021 | 490 | 0.350 |
Why?
|
| Residence Characteristics | 6 | 2024 | 2092 | 0.350 |
Why?
|
| Gene Fusion | 2 | 2012 | 355 | 0.340 |
Why?
|
| Trypsin Inhibitor, Kazal Pancreatic | 2 | 2023 | 30 | 0.340 |
Why?
|
| Mass Screening | 9 | 2023 | 5426 | 0.340 |
Why?
|
| Logistic Models | 18 | 2021 | 13249 | 0.330 |
Why?
|
| Sleep Disorders, Circadian Rhythm | 1 | 2012 | 196 | 0.330 |
Why?
|
| Polymorphism, Genetic | 7 | 2015 | 4243 | 0.330 |
Why?
|
| DNA-Binding Proteins | 3 | 2024 | 9567 | 0.330 |
Why?
|
| Antineoplastic Agents, Hormonal | 5 | 2019 | 1520 | 0.330 |
Why?
|
| Receptors, Calcium-Sensing | 3 | 2016 | 318 | 0.330 |
Why?
|
| Tooth Diseases | 1 | 2009 | 73 | 0.320 |
Why?
|
| Fatty Acids, Omega-3 | 5 | 2016 | 1390 | 0.320 |
Why?
|
| Endostatins | 1 | 2009 | 168 | 0.320 |
Why?
|
| Prescription Drugs | 1 | 2016 | 631 | 0.320 |
Why?
|
| Carrier Proteins | 2 | 2014 | 4935 | 0.320 |
Why?
|
| Sex Hormone-Binding Globulin | 7 | 2022 | 550 | 0.310 |
Why?
|
| DNA, Neoplasm | 3 | 2015 | 1743 | 0.310 |
Why?
|
| Population Surveillance | 8 | 2023 | 2598 | 0.310 |
Why?
|
| Diabetes Mellitus, Type 2 | 7 | 2024 | 12159 | 0.310 |
Why?
|
| Lung Neoplasms | 13 | 2024 | 13386 | 0.310 |
Why?
|
| Nuts | 2 | 2021 | 264 | 0.300 |
Why?
|
| Female | 100 | 2024 | 392552 | 0.300 |
Why?
|
| Receptors, Calcitriol | 5 | 2024 | 360 | 0.300 |
Why?
|
| Toll-Like Receptor 4 | 1 | 2011 | 577 | 0.290 |
Why?
|
| Survival Analysis | 17 | 2018 | 10088 | 0.290 |
Why?
|
| Acrylamides | 2 | 2009 | 259 | 0.280 |
Why?
|
| Ovarian Neoplasms | 8 | 2019 | 4872 | 0.280 |
Why?
|
| Estradiol | 9 | 2019 | 1937 | 0.280 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 1 | 4 | 2023 | 126 | 0.280 |
Why?
|
| Cooking | 1 | 2009 | 309 | 0.280 |
Why?
|
| Mouth Diseases | 1 | 2009 | 240 | 0.280 |
Why?
|
| Interleukin-6 | 4 | 2019 | 3210 | 0.280 |
Why?
|
| Alcohol Drinking | 10 | 2023 | 4027 | 0.280 |
Why?
|
| Circadian Rhythm | 6 | 2023 | 2569 | 0.270 |
Why?
|
| Epidemiology | 2 | 2019 | 280 | 0.270 |
Why?
|
| Phosphatidylinositol 3-Kinases | 4 | 2022 | 2864 | 0.270 |
Why?
|
| Sleep | 4 | 2020 | 4759 | 0.270 |
Why?
|
| Hemoglobins | 2 | 2009 | 1525 | 0.270 |
Why?
|
| Genes, BRCA1 | 1 | 2010 | 754 | 0.260 |
Why?
|
| Weight Gain | 6 | 2024 | 2349 | 0.260 |
Why?
|
| Finland | 6 | 2019 | 607 | 0.260 |
Why?
|
| Anticarcinogenic Agents | 3 | 2017 | 249 | 0.260 |
Why?
|
| Environment | 2 | 2023 | 1122 | 0.260 |
Why?
|
| Chromatin | 2 | 2017 | 2946 | 0.260 |
Why?
|
| Neoplasms, Hormone-Dependent | 4 | 2015 | 410 | 0.260 |
Why?
|
| Cause of Death | 5 | 2024 | 3688 | 0.260 |
Why?
|
| Models, Statistical | 3 | 2021 | 5081 | 0.250 |
Why?
|
| Cholesterol | 4 | 2019 | 2902 | 0.250 |
Why?
|
| Pandemics | 5 | 2020 | 8663 | 0.250 |
Why?
|
| Vitamins | 3 | 2024 | 1634 | 0.250 |
Why?
|
| Inflammation | 9 | 2023 | 10759 | 0.250 |
Why?
|
| BRCA2 Protein | 3 | 2020 | 797 | 0.250 |
Why?
|
| Pregnancy Complications, Neoplastic | 1 | 2007 | 258 | 0.240 |
Why?
|
| Health Behavior | 5 | 2022 | 2641 | 0.240 |
Why?
|
| Genetic Loci | 5 | 2021 | 2623 | 0.240 |
Why?
|
| Vitamin D-Binding Protein | 2 | 2018 | 130 | 0.240 |
Why?
|
| Mouth, Edentulous | 1 | 2005 | 82 | 0.230 |
Why?
|
| RNA, Messenger | 6 | 2018 | 12747 | 0.230 |
Why?
|
| Estriol | 2 | 2003 | 54 | 0.230 |
Why?
|
| Occult Blood | 1 | 2005 | 197 | 0.230 |
Why?
|
| Extracellular Matrix Proteins | 2 | 2021 | 830 | 0.230 |
Why?
|
| Confidence Intervals | 9 | 2021 | 2928 | 0.230 |
Why?
|
| Metabolomics | 4 | 2023 | 1658 | 0.230 |
Why?
|
| Mucins | 1 | 2007 | 569 | 0.230 |
Why?
|
| Cardiovascular Diseases | 7 | 2024 | 15521 | 0.230 |
Why?
|
| Spain | 2 | 2022 | 489 | 0.230 |
Why?
|
| Watchful Waiting | 4 | 2017 | 489 | 0.220 |
Why?
|
| Signal Transduction | 15 | 2024 | 23419 | 0.220 |
Why?
|
| Progesterone | 4 | 2008 | 742 | 0.220 |
Why?
|
| Embryonic and Fetal Development | 1 | 2004 | 420 | 0.220 |
Why?
|
| Diet Surveys | 5 | 2018 | 1161 | 0.220 |
Why?
|
| Health Occupations | 2 | 2019 | 223 | 0.220 |
Why?
|
| Private Sector | 1 | 2006 | 394 | 0.220 |
Why?
|
| Epigenomics | 2 | 2020 | 944 | 0.220 |
Why?
|
| Receptors, Adiponectin | 2 | 2015 | 81 | 0.220 |
Why?
|
| Persea | 1 | 2023 | 17 | 0.210 |
Why?
|
| Medical Oncology | 1 | 2015 | 2320 | 0.210 |
Why?
|
| Norway | 5 | 2019 | 499 | 0.210 |
Why?
|
| Waist Circumference | 2 | 2019 | 933 | 0.210 |
Why?
|
| Continuity of Patient Care | 2 | 2020 | 1069 | 0.210 |
Why?
|
| Kidney Neoplasms | 4 | 2018 | 4251 | 0.210 |
Why?
|
| Trace Elements | 2 | 2020 | 193 | 0.210 |
Why?
|
| Area Under Curve | 3 | 2016 | 1636 | 0.210 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2020 | 943 | 0.200 |
Why?
|
| Coronavirus Infections | 4 | 2020 | 3093 | 0.200 |
Why?
|
| Pneumonia, Viral | 4 | 2020 | 3215 | 0.200 |
Why?
|
| Diabetes Mellitus | 2 | 2020 | 5842 | 0.200 |
Why?
|
| Biological Transport | 2 | 2017 | 2081 | 0.200 |
Why?
|
| Glycoproteins | 1 | 2010 | 2203 | 0.200 |
Why?
|
| Sex Factors | 10 | 2020 | 10553 | 0.200 |
Why?
|
| Contraceptives, Oral | 1 | 2004 | 554 | 0.200 |
Why?
|
| Pregnancy | 17 | 2021 | 29893 | 0.200 |
Why?
|
| Somatotypes | 1 | 2022 | 41 | 0.200 |
Why?
|
| Monoclonal Gammopathy of Undetermined Significance | 1 | 2024 | 179 | 0.200 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 6 | 2018 | 3777 | 0.200 |
Why?
|
| Prolactin | 2 | 2003 | 625 | 0.200 |
Why?
|
| Caffeine | 2 | 2020 | 701 | 0.190 |
Why?
|
| Financial Management | 1 | 2023 | 160 | 0.190 |
Why?
|
| Proto-Oncogene Proteins c-ets | 1 | 2023 | 314 | 0.190 |
Why?
|
| Tristetraprolin | 2 | 2018 | 38 | 0.190 |
Why?
|
| DNA Repair-Deficiency Disorders | 1 | 2021 | 37 | 0.190 |
Why?
|
| Adiposity | 2 | 2024 | 1879 | 0.190 |
Why?
|
| Prostatic Hyperplasia | 3 | 2014 | 521 | 0.190 |
Why?
|
| Insulin-Like Growth Factor II | 2 | 2023 | 267 | 0.190 |
Why?
|
| Body Size | 2 | 2015 | 463 | 0.190 |
Why?
|
| Lighting | 1 | 2023 | 211 | 0.190 |
Why?
|
| Pregnancy-Associated Plasma Protein-A | 1 | 2021 | 61 | 0.190 |
Why?
|
| Inheritance Patterns | 2 | 2019 | 341 | 0.190 |
Why?
|
| Mortality | 7 | 2024 | 2896 | 0.190 |
Why?
|
| Age of Onset | 2 | 2024 | 3307 | 0.190 |
Why?
|
| Diet, Mediterranean | 3 | 2024 | 738 | 0.180 |
Why?
|
| Tumor Microenvironment | 4 | 2024 | 3875 | 0.180 |
Why?
|
| Adiponectin | 5 | 2019 | 1107 | 0.180 |
Why?
|
| Mutation, Missense | 1 | 2010 | 2567 | 0.180 |
Why?
|
| Atrophy | 2 | 2019 | 1633 | 0.180 |
Why?
|
| Antineoplastic Protocols | 1 | 2020 | 48 | 0.180 |
Why?
|
| Gestational Age | 2 | 2007 | 3580 | 0.180 |
Why?
|
| Biopsy | 7 | 2024 | 6781 | 0.180 |
Why?
|
| History, 20th Century | 3 | 2020 | 2765 | 0.180 |
Why?
|
| Animals | 32 | 2024 | 168089 | 0.180 |
Why?
|
| History, 21st Century | 2 | 2018 | 1567 | 0.180 |
Why?
|
| Menarche | 2 | 2016 | 532 | 0.180 |
Why?
|
| Plants | 1 | 2022 | 329 | 0.180 |
Why?
|
| Tooth Loss | 2 | 2017 | 200 | 0.170 |
Why?
|
| Public Opinion | 2 | 2001 | 485 | 0.170 |
Why?
|
| Bone Neoplasms | 4 | 2015 | 2527 | 0.170 |
Why?
|
| Squalene Monooxygenase | 2 | 2017 | 11 | 0.170 |
Why?
|
| Predictive Value of Tests | 9 | 2021 | 15308 | 0.170 |
Why?
|
| Behavioral Risk Factor Surveillance System | 3 | 2006 | 208 | 0.170 |
Why?
|
| Chromosome Mapping | 4 | 2022 | 4612 | 0.170 |
Why?
|
| Ki-67 Antigen | 3 | 2015 | 628 | 0.170 |
Why?
|
| Insulin-Like Growth Factor Binding Proteins | 2 | 2019 | 208 | 0.170 |
Why?
|
| Patient Acceptance of Health Care | 3 | 2019 | 3200 | 0.170 |
Why?
|
| Chemokine CCL21 | 1 | 2019 | 49 | 0.170 |
Why?
|
| Chemokine CCL11 | 1 | 2019 | 128 | 0.170 |
Why?
|
| 5-Methylcytosine | 1 | 2020 | 148 | 0.160 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2009 | 2047 | 0.160 |
Why?
|
| Intra-Abdominal Fat | 2 | 2019 | 612 | 0.160 |
Why?
|
| Prostatitis | 1 | 2019 | 102 | 0.160 |
Why?
|
| Receptors, Somatomedin | 1 | 2018 | 57 | 0.160 |
Why?
|
| Suicide | 3 | 2020 | 1602 | 0.160 |
Why?
|
| Multifactorial Inheritance | 3 | 2023 | 1387 | 0.160 |
Why?
|
| Disease Susceptibility | 3 | 2020 | 1791 | 0.160 |
Why?
|
| Trichomonas Vaginitis | 1 | 2018 | 33 | 0.160 |
Why?
|
| Lactic Acid | 1 | 2024 | 1139 | 0.160 |
Why?
|
| Risk-Taking | 3 | 2020 | 1038 | 0.160 |
Why?
|
| Transurethral Resection of Prostate | 2 | 2017 | 79 | 0.160 |
Why?
|
| Serine Proteinase Inhibitors | 1 | 2020 | 175 | 0.160 |
Why?
|
| Leuprolide | 1 | 2020 | 312 | 0.160 |
Why?
|
| Sleep Initiation and Maintenance Disorders | 2 | 2020 | 1081 | 0.160 |
Why?
|
| Medical History Taking | 2 | 2018 | 773 | 0.160 |
Why?
|
| Cell Line, Tumor | 14 | 2024 | 16954 | 0.160 |
Why?
|
| Paraffin Embedding | 2 | 2020 | 302 | 0.150 |
Why?
|
| DNA Damage | 3 | 2024 | 2443 | 0.150 |
Why?
|
| Proto-Oncogene Proteins c-sis | 1 | 2019 | 254 | 0.150 |
Why?
|
| Urinary Bladder Neoplasms | 3 | 2008 | 2223 | 0.150 |
Why?
|
| Dental Care | 1 | 2001 | 282 | 0.150 |
Why?
|
| Restaurants | 1 | 2001 | 231 | 0.150 |
Why?
|
| src-Family Kinases | 1 | 2020 | 536 | 0.150 |
Why?
|
| Linkage Disequilibrium | 5 | 2022 | 1994 | 0.150 |
Why?
|
| Colonoscopy | 2 | 2005 | 1395 | 0.150 |
Why?
|
| Telomere | 3 | 2022 | 939 | 0.150 |
Why?
|
| Racemases and Epimerases | 2 | 2011 | 114 | 0.150 |
Why?
|
| Arylalkylamine N-Acetyltransferase | 1 | 2017 | 13 | 0.150 |
Why?
|
| Histone Code | 2 | 2018 | 158 | 0.150 |
Why?
|
| Hypertension | 2 | 2017 | 8536 | 0.150 |
Why?
|
| Socioeconomic Factors | 9 | 2023 | 7804 | 0.150 |
Why?
|
| Dietary Fats | 4 | 2017 | 1994 | 0.150 |
Why?
|
| Gene Rearrangement | 2 | 2013 | 1125 | 0.150 |
Why?
|
| Sterol O-Acyltransferase | 1 | 2017 | 28 | 0.150 |
Why?
|
| Seasons | 4 | 2012 | 1518 | 0.140 |
Why?
|
| Prenatal Exposure Delayed Effects | 3 | 2004 | 2517 | 0.140 |
Why?
|
| Infectious Disease Transmission, Patient-to-Professional | 1 | 2020 | 250 | 0.140 |
Why?
|
| Metformin | 2 | 2016 | 910 | 0.140 |
Why?
|
| RNA, Neoplasm | 3 | 2015 | 748 | 0.140 |
Why?
|
| Life Expectancy | 1 | 2024 | 1242 | 0.140 |
Why?
|
| NADH, NADPH Oxidoreductases | 1 | 2017 | 94 | 0.140 |
Why?
|
| Tobacco Smoke Pollution | 1 | 2023 | 821 | 0.140 |
Why?
|
| Mutation | 7 | 2023 | 30004 | 0.140 |
Why?
|
| Estrogen Receptor beta | 2 | 2008 | 169 | 0.140 |
Why?
|
| Lymphoma, Non-Hodgkin | 1 | 2004 | 1372 | 0.140 |
Why?
|
| Organ Size | 3 | 2021 | 2253 | 0.140 |
Why?
|
| Mouth Neoplasms | 2 | 2001 | 596 | 0.140 |
Why?
|
| Treatment Outcome | 14 | 2018 | 64681 | 0.140 |
Why?
|
| Carcinoma, Hepatocellular | 5 | 2001 | 2293 | 0.140 |
Why?
|
| Hodgkin Disease | 1 | 2004 | 1379 | 0.140 |
Why?
|
| Poultry | 1 | 2016 | 80 | 0.140 |
Why?
|
| Social Class | 2 | 2023 | 1993 | 0.130 |
Why?
|
| Blood Platelets | 2 | 2020 | 2477 | 0.130 |
Why?
|
| Food Analysis | 2 | 2008 | 103 | 0.130 |
Why?
|
| Multivariate Analysis | 11 | 2021 | 12052 | 0.130 |
Why?
|
| Genes, Tumor Suppressor | 2 | 2019 | 1057 | 0.130 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2018 | 3163 | 0.130 |
Why?
|
| Leukemia | 1 | 2004 | 1518 | 0.130 |
Why?
|
| Delivery of Health Care | 3 | 2023 | 5333 | 0.130 |
Why?
|
| Europe | 5 | 2024 | 3423 | 0.130 |
Why?
|
| Epidemiologic Studies | 3 | 2023 | 677 | 0.130 |
Why?
|
| Neurosecretory Systems | 1 | 2017 | 223 | 0.130 |
Why?
|
| Pathology, Molecular | 1 | 2019 | 329 | 0.130 |
Why?
|
| Molecular Epidemiology | 3 | 2011 | 470 | 0.130 |
Why?
|
| Epigenesis, Genetic | 3 | 2020 | 3788 | 0.130 |
Why?
|
| Macular Degeneration | 1 | 2023 | 1009 | 0.130 |
Why?
|
| Alopecia | 1 | 2020 | 412 | 0.130 |
Why?
|
| Patient Compliance | 4 | 2017 | 2688 | 0.130 |
Why?
|
| Receptor, IGF Type 1 | 2 | 2018 | 380 | 0.130 |
Why?
|
| Nonsteroidal Anti-Androgens | 1 | 2015 | 9 | 0.120 |
Why?
|
| Fatty Acids, Omega-6 | 2 | 2014 | 225 | 0.120 |
Why?
|
| Pancreatic Ducts | 1 | 2017 | 329 | 0.120 |
Why?
|
| Liver Neoplasms | 6 | 2001 | 4310 | 0.120 |
Why?
|
| Histone Demethylases | 1 | 2018 | 322 | 0.120 |
Why?
|
| Attitude to Health | 2 | 2001 | 2026 | 0.120 |
Why?
|
| Eggs | 1 | 2016 | 182 | 0.120 |
Why?
|
| Phosphorus, Dietary | 1 | 2014 | 20 | 0.120 |
Why?
|
| Insurance Coverage | 1 | 2006 | 1935 | 0.120 |
Why?
|
| Testosterone | 6 | 2022 | 2472 | 0.120 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2003 | 955 | 0.120 |
Why?
|
| Neoplasms, Cystic, Mucinous, and Serous | 1 | 2017 | 194 | 0.120 |
Why?
|
| Cell Proliferation | 12 | 2020 | 10423 | 0.120 |
Why?
|
| Receptor, Insulin | 1 | 2018 | 836 | 0.120 |
Why?
|
| Tumor Suppressor Protein p53 | 2 | 2023 | 2915 | 0.120 |
Why?
|
| Peptide Fragments | 1 | 2007 | 5103 | 0.120 |
Why?
|
| Receptors, LDL | 1 | 2017 | 489 | 0.120 |
Why?
|
| History, Ancient | 1 | 2015 | 213 | 0.120 |
Why?
|
| Vitamin B Complex | 2 | 2009 | 299 | 0.120 |
Why?
|
| Clinical Trials as Topic | 2 | 2021 | 8002 | 0.120 |
Why?
|
| Smell | 1 | 2016 | 259 | 0.120 |
Why?
|
| Body Weights and Measures | 1 | 2015 | 208 | 0.120 |
Why?
|
| Digital Rectal Examination | 1 | 2014 | 41 | 0.120 |
Why?
|
| Body Weight | 3 | 2017 | 4618 | 0.120 |
Why?
|
| Rhinitis, Allergic, Seasonal | 1 | 2015 | 105 | 0.120 |
Why?
|
| Alleles | 7 | 2024 | 6857 | 0.120 |
Why?
|
| Insurance, Health | 1 | 2006 | 2493 | 0.110 |
Why?
|
| Fatty Acids, Unsaturated | 2 | 2011 | 540 | 0.110 |
Why?
|
| Tissue Fixation | 1 | 2015 | 241 | 0.110 |
Why?
|
| Lipoproteins, LDL | 1 | 2017 | 643 | 0.110 |
Why?
|
| Plaque, Amyloid | 1 | 2018 | 762 | 0.110 |
Why?
|
| Physicians | 6 | 2017 | 4584 | 0.110 |
Why?
|
| Electroretinography | 1 | 2016 | 524 | 0.110 |
Why?
|
| Androgens | 3 | 2024 | 1283 | 0.110 |
Why?
|
| Interleukin-10 | 1 | 2019 | 1176 | 0.110 |
Why?
|
| Estrogen Receptor alpha | 2 | 2008 | 582 | 0.110 |
Why?
|
| Minority Groups | 1 | 2021 | 1201 | 0.110 |
Why?
|
| Formaldehyde | 1 | 2015 | 357 | 0.110 |
Why?
|
| Genetic Markers | 4 | 2018 | 2599 | 0.110 |
Why?
|
| Fish Products | 1 | 2013 | 30 | 0.110 |
Why?
|
| Pancreatic Cyst | 1 | 2017 | 367 | 0.110 |
Why?
|
| Genes, myc | 2 | 2017 | 390 | 0.110 |
Why?
|
| Trinucleotide Repeats | 1 | 2014 | 257 | 0.110 |
Why?
|
| Cost of Illness | 1 | 2023 | 1936 | 0.110 |
Why?
|
| Massachusetts | 8 | 2006 | 8837 | 0.110 |
Why?
|
| Probability | 3 | 2009 | 2478 | 0.110 |
Why?
|
| Triglycerides | 2 | 2018 | 2457 | 0.110 |
Why?
|
| Peripheral Nerves | 1 | 2017 | 479 | 0.110 |
Why?
|
| Selenoproteins | 2 | 2016 | 215 | 0.110 |
Why?
|
| Selenoprotein P | 1 | 2012 | 33 | 0.110 |
Why?
|
| Pancreatic Neoplasms | 3 | 2020 | 5366 | 0.100 |
Why?
|
| Cell Growth Processes | 1 | 2013 | 382 | 0.100 |
Why?
|
| Menopause | 1 | 2001 | 1646 | 0.100 |
Why?
|
| ABO Blood-Group System | 1 | 2015 | 381 | 0.100 |
Why?
|
| Testicular Neoplasms | 1 | 2019 | 801 | 0.100 |
Why?
|
| Retinoid X Receptor alpha | 1 | 2012 | 16 | 0.100 |
Why?
|
| Urban Population | 1 | 2001 | 2036 | 0.100 |
Why?
|
| Overweight | 2 | 2017 | 2418 | 0.100 |
Why?
|
| Lipoproteins, HDL | 1 | 2017 | 675 | 0.100 |
Why?
|
| C-Peptide | 2 | 2019 | 442 | 0.100 |
Why?
|
| Bayes Theorem | 4 | 2024 | 2329 | 0.100 |
Why?
|
| Bread | 1 | 2012 | 23 | 0.100 |
Why?
|
| 25-Hydroxyvitamin D3 1-alpha-Hydroxylase | 1 | 2012 | 57 | 0.100 |
Why?
|
| Germ Cells | 3 | 2023 | 632 | 0.100 |
Why?
|
| Chromosomal Instability | 1 | 2013 | 178 | 0.100 |
Why?
|
| Steroid Hydroxylases | 1 | 2012 | 93 | 0.100 |
Why?
|
| Cyclooxygenase 1 | 1 | 2012 | 97 | 0.100 |
Why?
|
| SOX9 Transcription Factor | 1 | 2013 | 145 | 0.100 |
Why?
|
| Plant Extracts | 1 | 2016 | 496 | 0.100 |
Why?
|
| Gonadotropin-Releasing Hormone | 1 | 2018 | 1146 | 0.100 |
Why?
|
| Endometriosis | 1 | 2020 | 870 | 0.100 |
Why?
|
| Birth Order | 2 | 2004 | 95 | 0.100 |
Why?
|
| Apoptosis | 6 | 2020 | 9478 | 0.100 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 3 | 2021 | 3803 | 0.100 |
Why?
|
| Family Health | 1 | 2017 | 1254 | 0.100 |
Why?
|
| Antineoplastic Agents, Phytogenic | 1 | 2016 | 620 | 0.100 |
Why?
|
| Double-Blind Method | 5 | 2017 | 12341 | 0.100 |
Why?
|
| Membrane Proteins | 1 | 2009 | 7851 | 0.100 |
Why?
|
| Greece | 6 | 2001 | 340 | 0.100 |
Why?
|
| Calcium, Dietary | 1 | 2014 | 529 | 0.100 |
Why?
|
| Hypercholesterolemia | 1 | 2018 | 1141 | 0.100 |
Why?
|
| ROC Curve | 2 | 2016 | 3584 | 0.100 |
Why?
|
| Adolescent | 24 | 2022 | 88300 | 0.100 |
Why?
|
| Eating | 3 | 2016 | 1535 | 0.100 |
Why?
|
| Chemokine CCL2 | 1 | 2014 | 602 | 0.090 |
Why?
|
| Mendelian Randomization Analysis | 3 | 2023 | 1010 | 0.090 |
Why?
|
| Consensus | 1 | 2021 | 3134 | 0.090 |
Why?
|
| Prostatic Intraepithelial Neoplasia | 1 | 2011 | 81 | 0.090 |
Why?
|
| Epithelial Cells | 4 | 2017 | 3671 | 0.090 |
Why?
|
| Basic Helix-Loop-Helix Transcription Factors | 1 | 2017 | 1132 | 0.090 |
Why?
|
| Prostatic Secretory Proteins | 1 | 2010 | 24 | 0.090 |
Why?
|
| Neoplasm Proteins | 2 | 2020 | 3594 | 0.090 |
Why?
|
| Parity | 5 | 2008 | 929 | 0.090 |
Why?
|
| Interleukin-8 | 1 | 2014 | 696 | 0.090 |
Why?
|
| Data Collection | 1 | 2020 | 3320 | 0.090 |
Why?
|
| Calcium | 2 | 2015 | 5719 | 0.090 |
Why?
|
| Heart Transplantation | 1 | 2024 | 3258 | 0.090 |
Why?
|
| DNA Methylation | 3 | 2020 | 4384 | 0.090 |
Why?
|
| Nuclear Receptor Coactivators | 1 | 2010 | 60 | 0.090 |
Why?
|
| Dietary Fats, Unsaturated | 1 | 2011 | 224 | 0.090 |
Why?
|
| Reproducibility of Results | 7 | 2023 | 20118 | 0.090 |
Why?
|
| In Situ Hybridization, Fluorescence | 3 | 2018 | 2509 | 0.090 |
Why?
|
| Chromosomes, Human, Pair 10 | 1 | 2010 | 277 | 0.090 |
Why?
|
| Up-Regulation | 3 | 2014 | 4111 | 0.080 |
Why?
|
| Promoter Regions, Genetic | 1 | 2021 | 5773 | 0.080 |
Why?
|
| Nuclear Proteins | 1 | 2024 | 5783 | 0.080 |
Why?
|
| Maillard Reaction | 1 | 2009 | 8 | 0.080 |
Why?
|
| Microarray Analysis | 2 | 2011 | 748 | 0.080 |
Why?
|
| Apolipoproteins E | 1 | 2015 | 1443 | 0.080 |
Why?
|
| Angiotensin-Converting Enzyme Inhibitors | 1 | 2016 | 1504 | 0.080 |
Why?
|
| Epoxy Compounds | 1 | 2009 | 137 | 0.080 |
Why?
|
| Models, Genetic | 1 | 2019 | 3430 | 0.080 |
Why?
|
| Healthcare Disparities | 2 | 2023 | 3354 | 0.080 |
Why?
|
| Radiation Tolerance | 1 | 2011 | 478 | 0.080 |
Why?
|
| Patient Education as Topic | 2 | 2019 | 2317 | 0.080 |
Why?
|
| High-Throughput Nucleotide Sequencing | 1 | 2021 | 3634 | 0.080 |
Why?
|
| Cytoplasm | 2 | 2016 | 1498 | 0.080 |
Why?
|
| Central Nervous System Depressants | 1 | 2009 | 164 | 0.080 |
Why?
|
| Interviews as Topic | 3 | 2017 | 2697 | 0.080 |
Why?
|
| Sleep Deprivation | 1 | 2015 | 847 | 0.080 |
Why?
|
| Thyroid Neoplasms | 1 | 2022 | 2330 | 0.080 |
Why?
|
| Wnt1 Protein | 1 | 2008 | 122 | 0.080 |
Why?
|
| Head and Neck Neoplasms | 2 | 2019 | 2894 | 0.080 |
Why?
|
| Birth Intervals | 1 | 2008 | 51 | 0.080 |
Why?
|
| Self Report | 4 | 2021 | 3727 | 0.080 |
Why?
|
| Epidemiologic Methods | 5 | 2019 | 1336 | 0.080 |
Why?
|
| Age Distribution | 5 | 2006 | 2871 | 0.080 |
Why?
|
| Lipids | 1 | 2019 | 3331 | 0.080 |
Why?
|
| Nutrition Policy | 1 | 2012 | 466 | 0.070 |
Why?
|
| Vitamin B 6 | 1 | 2009 | 234 | 0.070 |
Why?
|
| Stress, Physiological | 1 | 2015 | 1405 | 0.070 |
Why?
|
| Dinucleotide Repeats | 1 | 2007 | 28 | 0.070 |
Why?
|
| Rectal Neoplasms | 1 | 2017 | 1156 | 0.070 |
Why?
|
| Palmitic Acid | 1 | 2008 | 149 | 0.070 |
Why?
|
| Body Composition | 1 | 2017 | 2427 | 0.070 |
Why?
|
| In Situ Nick-End Labeling | 1 | 2009 | 613 | 0.070 |
Why?
|
| Chromosomes, Human, Pair 17 | 1 | 2009 | 418 | 0.070 |
Why?
|
| Cell Transformation, Neoplastic | 1 | 2017 | 2820 | 0.070 |
Why?
|
| NF-kappa B | 1 | 2016 | 2475 | 0.070 |
Why?
|
| Young Adult | 13 | 2022 | 59222 | 0.070 |
Why?
|
| Sex Ratio | 1 | 2007 | 107 | 0.070 |
Why?
|
| Benchmarking | 1 | 2014 | 1045 | 0.070 |
Why?
|
| Genes, BRCA2 | 2 | 2021 | 591 | 0.070 |
Why?
|
| Molecular Sequence Annotation | 2 | 2021 | 518 | 0.070 |
Why?
|
| Phenotype | 5 | 2022 | 16575 | 0.070 |
Why?
|
| Premenopause | 2 | 2009 | 1039 | 0.070 |
Why?
|
| Endometrial Neoplasms | 2 | 2010 | 1366 | 0.070 |
Why?
|
| Genetic Testing | 1 | 2020 | 3537 | 0.070 |
Why?
|
| Down-Regulation | 1 | 2014 | 2916 | 0.070 |
Why?
|
| Longitudinal Studies | 6 | 2023 | 14610 | 0.070 |
Why?
|
| Mice | 13 | 2024 | 81330 | 0.070 |
Why?
|
| Pilot Projects | 2 | 2017 | 8642 | 0.070 |
Why?
|
| Retrospective Studies | 13 | 2023 | 80675 | 0.070 |
Why?
|
| Gene Knockdown Techniques | 3 | 2018 | 1602 | 0.070 |
Why?
|
| Veterans | 1 | 2020 | 2656 | 0.070 |
Why?
|
| Smoking Cessation | 1 | 2018 | 2056 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 6 | 2018 | 10218 | 0.070 |
Why?
|
| Atrial Natriuretic Factor | 1 | 2007 | 350 | 0.070 |
Why?
|
| Alcoholism | 3 | 2001 | 1973 | 0.070 |
Why?
|
| Mice, SCID | 3 | 2018 | 2621 | 0.070 |
Why?
|
| Forecasting | 1 | 2015 | 2928 | 0.070 |
Why?
|
| Phenylthiohydantoin | 2 | 2018 | 205 | 0.070 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2017 | 1726 | 0.070 |
Why?
|
| Hypoglycemic Agents | 2 | 2020 | 3089 | 0.070 |
Why?
|
| Multiple Myeloma | 1 | 2024 | 5145 | 0.070 |
Why?
|
| Software | 1 | 2020 | 4431 | 0.060 |
Why?
|
| Health Status | 4 | 2017 | 4077 | 0.060 |
Why?
|
| Nitriles | 3 | 2018 | 971 | 0.060 |
Why?
|
| Prenatal Nutritional Physiological Phenomena | 2 | 2004 | 160 | 0.060 |
Why?
|
| Toll-Like Receptors | 1 | 2009 | 575 | 0.060 |
Why?
|
| Protein Array Analysis | 1 | 2007 | 399 | 0.060 |
Why?
|
| Stress, Psychological | 3 | 2010 | 4487 | 0.060 |
Why?
|
| Leptin | 2 | 2013 | 1595 | 0.060 |
Why?
|
| Bile Duct Neoplasms | 2 | 2001 | 607 | 0.060 |
Why?
|
| Transcription, Genetic | 2 | 2017 | 7571 | 0.060 |
Why?
|
| Tumor Suppressor Proteins | 1 | 2015 | 2803 | 0.060 |
Why?
|
| Orchiectomy | 3 | 2014 | 463 | 0.060 |
Why?
|
| Hormones | 3 | 2008 | 868 | 0.060 |
Why?
|
| SEER Program | 3 | 2019 | 1453 | 0.060 |
Why?
|
| Vegetables | 3 | 2016 | 1192 | 0.060 |
Why?
|
| Dentition, Permanent | 1 | 2005 | 22 | 0.060 |
Why?
|
| Pit and Fissure Sealants | 1 | 2005 | 27 | 0.060 |
Why?
|
| Dementia | 1 | 2019 | 2684 | 0.060 |
Why?
|
| Self Disclosure | 1 | 2006 | 249 | 0.060 |
Why?
|
| Marital Status | 2 | 2024 | 425 | 0.060 |
Why?
|
| Substance-Related Disorders | 2 | 2020 | 4413 | 0.060 |
Why?
|
| Drug Synergism | 2 | 2020 | 1756 | 0.060 |
Why?
|
| Gravidity | 1 | 2004 | 50 | 0.060 |
Why?
|
| Immunoenzyme Techniques | 1 | 2008 | 1703 | 0.060 |
Why?
|
| Research Design | 3 | 2017 | 6180 | 0.060 |
Why?
|
| Nerve Tissue Proteins | 1 | 2017 | 4404 | 0.060 |
Why?
|
| Angiotensin II | 1 | 2007 | 848 | 0.060 |
Why?
|
| Survivors | 1 | 2015 | 2369 | 0.060 |
Why?
|
| Food Industry | 1 | 2005 | 67 | 0.060 |
Why?
|
| Haplotypes | 2 | 2022 | 2715 | 0.060 |
Why?
|
| Dietary Proteins | 2 | 2007 | 951 | 0.060 |
Why?
|
| Fatty Acids | 1 | 2012 | 1807 | 0.060 |
Why?
|
| Netherlands | 1 | 2009 | 2222 | 0.060 |
Why?
|
| Terminally Ill | 1 | 2006 | 240 | 0.060 |
Why?
|
| Referral and Consultation | 1 | 2017 | 3608 | 0.060 |
Why?
|
| Molar | 1 | 2005 | 154 | 0.060 |
Why?
|
| Diet, Carbohydrate-Restricted | 1 | 2007 | 263 | 0.060 |
Why?
|
| Prevalence | 4 | 2018 | 15721 | 0.060 |
Why?
|
| Mice, Nude | 3 | 2020 | 3606 | 0.060 |
Why?
|
| Biomedical Research | 1 | 2019 | 3434 | 0.060 |
Why?
|
| Mice, Transgenic | 5 | 2019 | 9520 | 0.060 |
Why?
|
| Quality Indicators, Health Care | 1 | 2014 | 1789 | 0.060 |
Why?
|
| Disease-Free Survival | 4 | 2017 | 6819 | 0.060 |
Why?
|
| Precancerous Conditions | 1 | 2010 | 982 | 0.060 |
Why?
|
| Gene Frequency | 2 | 2022 | 3603 | 0.060 |
Why?
|
| Infant, Newborn | 7 | 2015 | 26200 | 0.050 |
Why?
|
| Chromosomes, Human, Pair 19 | 1 | 2024 | 350 | 0.050 |
Why?
|
| Cytokines | 1 | 2018 | 7386 | 0.050 |
Why?
|
| Fruit | 2 | 2016 | 1158 | 0.050 |
Why?
|
| Ethanol | 1 | 2009 | 1322 | 0.050 |
Why?
|
| Estrogens | 2 | 2008 | 1522 | 0.050 |
Why?
|
| Hyperemesis Gravidarum | 1 | 2003 | 23 | 0.050 |
Why?
|
| beta Catenin | 1 | 2008 | 1042 | 0.050 |
Why?
|
| Health Maintenance Organizations | 1 | 2006 | 658 | 0.050 |
Why?
|
| Melanoma | 1 | 2022 | 5694 | 0.050 |
Why?
|
| Oncogenes | 1 | 2009 | 1220 | 0.050 |
Why?
|
| Preconception Care | 1 | 2004 | 141 | 0.050 |
Why?
|
| Adaptor Proteins, Signal Transducing | 2 | 2016 | 2897 | 0.050 |
Why?
|
| Nutrition Surveys | 2 | 2013 | 1723 | 0.050 |
Why?
|
| Analysis of Variance | 2 | 2009 | 6223 | 0.050 |
Why?
|
| Stress Disorders, Post-Traumatic | 1 | 2020 | 4575 | 0.050 |
Why?
|
| Lymphatic Diseases | 1 | 2004 | 320 | 0.050 |
Why?
|
| Anthropometry | 2 | 2019 | 1338 | 0.050 |
Why?
|
| Mucin-1 | 1 | 2007 | 538 | 0.050 |
Why?
|
| Sex Distribution | 2 | 2005 | 2277 | 0.050 |
Why?
|
| Clinical Trials, Phase III as Topic | 2 | 2018 | 858 | 0.050 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2014 | 4340 | 0.050 |
Why?
|
| Mice, Inbred NOD | 2 | 2018 | 1822 | 0.050 |
Why?
|
| Hot Temperature | 1 | 2009 | 1434 | 0.050 |
Why?
|
| Central Nervous System Stimulants | 1 | 2011 | 1176 | 0.050 |
Why?
|
| Social Support | 2 | 2024 | 2175 | 0.050 |
Why?
|
| Boston | 6 | 2017 | 9327 | 0.050 |
Why?
|
| Environmental Monitoring | 1 | 2009 | 1460 | 0.050 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2024 | 36415 | 0.050 |
Why?
|
| Osteoarthritis | 1 | 2010 | 1063 | 0.050 |
Why?
|
| Vietnam | 1 | 2023 | 406 | 0.050 |
Why?
|
| Environmental Exposure | 2 | 2009 | 4479 | 0.050 |
Why?
|
| Health Knowledge, Attitudes, Practice | 3 | 2013 | 4014 | 0.050 |
Why?
|
| Laparoscopy | 1 | 2014 | 2035 | 0.050 |
Why?
|
| Class Ia Phosphatidylinositol 3-Kinase | 1 | 2022 | 77 | 0.050 |
Why?
|
| Benzamides | 2 | 2018 | 1371 | 0.050 |
Why?
|
| Blood Pressure | 1 | 2017 | 8479 | 0.050 |
Why?
|
| Child | 10 | 2022 | 80154 | 0.050 |
Why?
|
| Fetal Development | 1 | 2007 | 768 | 0.050 |
Why?
|
| Models, Animal | 1 | 2008 | 2114 | 0.050 |
Why?
|
| Hepatitis, Chronic | 1 | 2001 | 53 | 0.050 |
Why?
|
| Carcinoma, Transitional Cell | 1 | 2008 | 782 | 0.050 |
Why?
|
| Guideline Adherence | 1 | 2012 | 2220 | 0.050 |
Why?
|
| Courtship | 1 | 2001 | 34 | 0.050 |
Why?
|
| Needle-Exchange Programs | 1 | 2001 | 26 | 0.050 |
Why?
|
| Placenta | 2 | 2008 | 1711 | 0.050 |
Why?
|
| Models, Theoretical | 2 | 2016 | 3571 | 0.050 |
Why?
|
| Maternal Age | 1 | 2004 | 809 | 0.050 |
Why?
|
| Fish Oils | 2 | 2016 | 483 | 0.050 |
Why?
|
| Xenograft Model Antitumor Assays | 2 | 2020 | 3593 | 0.050 |
Why?
|
| Databases, Factual | 2 | 2020 | 7965 | 0.050 |
Why?
|
| Hepatitis, Viral, Human | 1 | 2001 | 140 | 0.050 |
Why?
|
| Micronutrients | 1 | 2004 | 381 | 0.050 |
Why?
|
| Dental Caries | 1 | 2005 | 427 | 0.050 |
Why?
|
| Battered Women | 1 | 2000 | 35 | 0.050 |
Why?
|
| Evidence-Based Medicine | 1 | 2013 | 3691 | 0.040 |
Why?
|
| Gabexate | 1 | 2020 | 12 | 0.040 |
Why?
|
| Computational Biology | 3 | 2020 | 3499 | 0.040 |
Why?
|
| Adipocytes | 1 | 2007 | 1190 | 0.040 |
Why?
|
| Gene Dosage | 2 | 2018 | 1217 | 0.040 |
Why?
|
| Stathmin | 1 | 2020 | 70 | 0.040 |
Why?
|
| Antineoplastic Agents | 2 | 2020 | 13632 | 0.040 |
Why?
|
| Hepatitis B virus | 2 | 2001 | 527 | 0.040 |
Why?
|
| Lymphatic Metastasis | 3 | 2014 | 2913 | 0.040 |
Why?
|
| Insulin | 3 | 2022 | 6588 | 0.040 |
Why?
|
| Proxy | 1 | 2001 | 151 | 0.040 |
Why?
|
| Longevity | 1 | 2007 | 1063 | 0.040 |
Why?
|
| Siblings | 1 | 2004 | 824 | 0.040 |
Why?
|
| Dihydroergotoxine | 1 | 1979 | 21 | 0.040 |
Why?
|
| Infant, Low Birth Weight | 1 | 2004 | 869 | 0.040 |
Why?
|
| Leukemia, Myelogenous, Chronic, BCR-ABL Positive | 1 | 2004 | 686 | 0.040 |
Why?
|
| Gas Chromatography-Mass Spectrometry | 1 | 2020 | 353 | 0.040 |
Why?
|
| Carcinoma | 2 | 2008 | 2330 | 0.040 |
Why?
|
| Mental Recall | 1 | 2006 | 1221 | 0.040 |
Why?
|
| Condoms | 1 | 2001 | 331 | 0.040 |
Why?
|
| Guanidines | 1 | 2020 | 194 | 0.040 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2022 | 2455 | 0.040 |
Why?
|
| Sample Size | 1 | 2022 | 843 | 0.040 |
Why?
|
| Fanconi Anemia | 1 | 2021 | 324 | 0.040 |
Why?
|
| Esters | 1 | 2020 | 210 | 0.040 |
Why?
|
| Spouse Abuse | 1 | 2000 | 182 | 0.040 |
Why?
|
| Housing | 1 | 2004 | 669 | 0.040 |
Why?
|
| Receptors, Adrenergic, alpha | 1 | 1979 | 146 | 0.040 |
Why?
|
| Lipogenesis | 1 | 2020 | 214 | 0.040 |
Why?
|
| Receptors, Adrenergic | 1 | 1979 | 155 | 0.040 |
Why?
|
| Uncertainty | 1 | 2024 | 752 | 0.040 |
Why?
|
| Breast Neoplasms, Male | 1 | 2000 | 212 | 0.040 |
Why?
|
| Southeastern United States | 1 | 2018 | 91 | 0.040 |
Why?
|
| DNA Mismatch Repair | 1 | 2021 | 428 | 0.040 |
Why?
|
| Survival | 1 | 2019 | 161 | 0.040 |
Why?
|
| Quantitative Trait Loci | 2 | 2018 | 2113 | 0.040 |
Why?
|
| European Union | 1 | 2019 | 157 | 0.040 |
Why?
|
| Uterine Contraction | 1 | 1979 | 91 | 0.040 |
Why?
|
| Gene Regulatory Networks | 2 | 2018 | 1743 | 0.040 |
Why?
|
| Child, Preschool | 5 | 2022 | 42225 | 0.040 |
Why?
|
| Demography | 1 | 2003 | 1641 | 0.040 |
Why?
|
| Energy Intake | 2 | 2003 | 2133 | 0.040 |
Why?
|
| Glycolysis | 1 | 2022 | 836 | 0.040 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2015 | 6486 | 0.040 |
Why?
|
| Myometrium | 1 | 1979 | 174 | 0.040 |
Why?
|
| Hematologic Tests | 1 | 2019 | 239 | 0.040 |
Why?
|
| Biological Availability | 1 | 2018 | 389 | 0.040 |
Why?
|
| Statistics as Topic | 1 | 2004 | 2359 | 0.040 |
Why?
|
| Binding, Competitive | 2 | 2015 | 1140 | 0.040 |
Why?
|
| Health Records, Personal | 1 | 2019 | 127 | 0.040 |
Why?
|
| Health Status Indicators | 1 | 2003 | 970 | 0.040 |
Why?
|
| China | 2 | 2020 | 2374 | 0.040 |
Why?
|
| Ireland | 1 | 2017 | 169 | 0.040 |
Why?
|
| Italy | 2 | 2018 | 844 | 0.040 |
Why?
|
| London | 1 | 2017 | 233 | 0.040 |
Why?
|
| Maternal Exposure | 1 | 2004 | 1067 | 0.040 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2018 | 294 | 0.040 |
Why?
|
| Postoperative Complications | 3 | 2024 | 15637 | 0.040 |
Why?
|
| Chromosomes, Human, Y | 1 | 2018 | 161 | 0.040 |
Why?
|
| Seroepidemiologic Studies | 1 | 2018 | 399 | 0.030 |
Why?
|
| Reproductive History | 2 | 2008 | 210 | 0.030 |
Why?
|
| Androstenes | 1 | 2018 | 181 | 0.030 |
Why?
|
| Hepacivirus | 2 | 2001 | 1330 | 0.030 |
Why?
|
| Pregnancy Outcome | 2 | 2004 | 2923 | 0.030 |
Why?
|
| Cell Count | 1 | 2020 | 1831 | 0.030 |
Why?
|
| Long Interspersed Nucleotide Elements | 1 | 2018 | 330 | 0.030 |
Why?
|
| Pregnancy Trimester, Second | 3 | 2004 | 732 | 0.030 |
Why?
|
| Adaptive Immunity | 1 | 2021 | 724 | 0.030 |
Why?
|
| Thioredoxin Reductase 2 | 1 | 2016 | 25 | 0.030 |
Why?
|
| Thioredoxin Reductase 1 | 1 | 2016 | 32 | 0.030 |
Why?
|
| Selenium-Binding Proteins | 1 | 2016 | 18 | 0.030 |
Why?
|
| Regression Analysis | 4 | 2009 | 6345 | 0.030 |
Why?
|
| Cell Differentiation | 2 | 2011 | 11512 | 0.030 |
Why?
|
| Fluorescent Antibody Technique | 1 | 2020 | 2468 | 0.030 |
Why?
|
| Genome, Human | 2 | 2022 | 4423 | 0.030 |
Why?
|
| Health Surveys | 2 | 2008 | 4037 | 0.030 |
Why?
|
| Psychometrics | 1 | 2006 | 3061 | 0.030 |
Why?
|
| Asthma | 1 | 2015 | 6230 | 0.030 |
Why?
|
| Geography | 1 | 2018 | 652 | 0.030 |
Why?
|
| Tomography, X-Ray Computed | 1 | 2019 | 20588 | 0.030 |
Why?
|
| Linear Models | 4 | 2014 | 5869 | 0.030 |
Why?
|
| Fetus | 1 | 2003 | 1864 | 0.030 |
Why?
|
| Models, Biological | 3 | 2020 | 9458 | 0.030 |
Why?
|
| Plasma | 1 | 2019 | 586 | 0.030 |
Why?
|
| Adipose Tissue | 1 | 2007 | 3313 | 0.030 |
Why?
|
| Health Services | 1 | 2000 | 750 | 0.030 |
Why?
|
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 1 | 2004 | 1549 | 0.030 |
Why?
|
| CpG Islands | 1 | 2020 | 1190 | 0.030 |
Why?
|
| Cholangiocarcinoma | 1 | 2001 | 554 | 0.030 |
Why?
|
| Individuality | 1 | 2017 | 303 | 0.030 |
Why?
|
| Uterus | 1 | 1979 | 651 | 0.030 |
Why?
|
| Violence | 1 | 2001 | 935 | 0.030 |
Why?
|
| Clinical Laboratory Techniques | 1 | 2020 | 746 | 0.030 |
Why?
|
| Phospholipids | 1 | 2018 | 784 | 0.030 |
Why?
|
| Glutathione Peroxidase | 1 | 2016 | 258 | 0.030 |
Why?
|
| Energy Metabolism | 1 | 2006 | 2877 | 0.030 |
Why?
|
| Tumor Escape | 1 | 2017 | 371 | 0.030 |
Why?
|
| DNA Primers | 2 | 2009 | 2814 | 0.030 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 1 | 2021 | 1651 | 0.030 |
Why?
|
| Dehydroepiandrosterone Sulfate | 1 | 2015 | 241 | 0.030 |
Why?
|
| Transfection | 2 | 2015 | 5748 | 0.030 |
Why?
|
| INDEL Mutation | 1 | 2015 | 265 | 0.030 |
Why?
|
| Congresses as Topic | 1 | 2019 | 803 | 0.030 |
Why?
|
| Aging | 1 | 2013 | 8702 | 0.030 |
Why?
|
| Taxoids | 1 | 2017 | 668 | 0.030 |
Why?
|
| Pre-Eclampsia | 1 | 2003 | 1233 | 0.030 |
Why?
|
| RNA Interference | 2 | 2015 | 2816 | 0.030 |
Why?
|
| Immunoprecipitation | 1 | 2016 | 874 | 0.030 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2015 | 296 | 0.030 |
Why?
|
| Tumor Burden | 1 | 2019 | 1892 | 0.030 |
Why?
|
| Internet | 1 | 2006 | 3096 | 0.030 |
Why?
|
| Hematopoiesis | 1 | 2023 | 2049 | 0.030 |
Why?
|
| Transcription Factors | 1 | 2013 | 12101 | 0.030 |
Why?
|
| Educational Status | 1 | 2001 | 2510 | 0.030 |
Why?
|
| Infant | 3 | 2017 | 36170 | 0.030 |
Why?
|
| Multicenter Studies as Topic | 1 | 2018 | 1702 | 0.030 |
Why?
|
| Tumor Cells, Cultured | 1 | 2020 | 6125 | 0.030 |
Why?
|
| Hospitals, General | 1 | 2017 | 799 | 0.030 |
Why?
|
| Epithelium | 1 | 2017 | 1603 | 0.030 |
Why?
|
| Self Efficacy | 1 | 2017 | 636 | 0.030 |
Why?
|
| Chromosome Aberrations | 1 | 2019 | 1767 | 0.030 |
Why?
|
| Thromboxane B2 | 1 | 2012 | 143 | 0.030 |
Why?
|
| Health Care Surveys | 2 | 2014 | 2425 | 0.030 |
Why?
|
| Dihydrotestosterone | 1 | 2013 | 195 | 0.030 |
Why?
|
| Proto-Oncogene Proteins p21(ras) | 1 | 2020 | 1746 | 0.030 |
Why?
|
| Practice Guidelines as Topic | 1 | 2009 | 7400 | 0.020 |
Why?
|
| Income | 1 | 2001 | 1869 | 0.020 |
Why?
|
| Acetylation | 1 | 2014 | 1050 | 0.020 |
Why?
|
| In Situ Hybridization | 1 | 2015 | 1900 | 0.020 |
Why?
|
| Clinical Protocols | 1 | 2017 | 1436 | 0.020 |
Why?
|
| Genital Neoplasms, Female | 1 | 2017 | 533 | 0.020 |
Why?
|
| Meat | 1 | 2014 | 584 | 0.020 |
Why?
|
| Fatty Acid Desaturases | 1 | 2011 | 101 | 0.020 |
Why?
|
| Health Status Disparities | 1 | 2023 | 1847 | 0.020 |
Why?
|
| Patient Selection | 2 | 2017 | 4246 | 0.020 |
Why?
|
| Mice, Knockout | 2 | 2020 | 14392 | 0.020 |
Why?
|
| Liver Cirrhosis | 1 | 2001 | 1932 | 0.020 |
Why?
|
| Nomograms | 1 | 2013 | 230 | 0.020 |
Why?
|
| Serotonin | 1 | 2015 | 1042 | 0.020 |
Why?
|
| Drug Therapy, Combination | 1 | 2020 | 6304 | 0.020 |
Why?
|
| Disease Outbreaks | 1 | 2020 | 1747 | 0.020 |
Why?
|
| Health Services Misuse | 1 | 2012 | 244 | 0.020 |
Why?
|
| Reference Values | 2 | 2012 | 4921 | 0.020 |
Why?
|
| Physician-Patient Relations | 1 | 2004 | 3253 | 0.020 |
Why?
|
| Hematopoietic Stem Cells | 1 | 2023 | 3390 | 0.020 |
Why?
|
| Severity of Illness Index | 1 | 2008 | 15841 | 0.020 |
Why?
|
| Diet, Fat-Restricted | 1 | 2012 | 329 | 0.020 |
Why?
|
| Australia | 1 | 2014 | 1246 | 0.020 |
Why?
|
| Blood Loss, Surgical | 1 | 2014 | 637 | 0.020 |
Why?
|
| Fatigue | 1 | 2017 | 1550 | 0.020 |
Why?
|
| Glioma | 1 | 2004 | 3452 | 0.020 |
Why?
|
| Brain | 1 | 2016 | 27094 | 0.020 |
Why?
|
| Enzyme Activation | 1 | 2015 | 3577 | 0.020 |
Why?
|
| Metabolic Diseases | 1 | 2016 | 680 | 0.020 |
Why?
|
| Vitamin D Deficiency | 1 | 2019 | 1388 | 0.020 |
Why?
|
| Immunity, Innate | 1 | 2021 | 3044 | 0.020 |
Why?
|
| Single-Cell Analysis | 1 | 2020 | 2452 | 0.020 |
Why?
|
| Databases, Genetic | 1 | 2016 | 1741 | 0.020 |
Why?
|
| Affect | 1 | 2017 | 1486 | 0.020 |
Why?
|
| Penetrance | 1 | 2011 | 382 | 0.020 |
Why?
|
| Neoplasm Transplantation | 1 | 2013 | 2010 | 0.020 |
Why?
|
| Chi-Square Distribution | 1 | 2015 | 3418 | 0.020 |
Why?
|
| Causality | 2 | 2009 | 1244 | 0.020 |
Why?
|
| Oncogene Proteins | 1 | 2013 | 718 | 0.020 |
Why?
|
| Respiration, Artificial | 1 | 2020 | 2631 | 0.020 |
Why?
|
| Influenza, Human | 1 | 2020 | 1521 | 0.020 |
Why?
|
| Comorbidity | 3 | 2011 | 10516 | 0.020 |
Why?
|
| Algorithms | 2 | 2020 | 14025 | 0.020 |
Why?
|
| Inflammation Mediators | 1 | 2017 | 1885 | 0.020 |
Why?
|
| Bromodeoxyuridine | 1 | 2009 | 310 | 0.020 |
Why?
|
| Gene Knockout Techniques | 1 | 2011 | 801 | 0.020 |
Why?
|
| Cell Movement | 1 | 2020 | 5195 | 0.020 |
Why?
|
| Leukemia, Myeloid, Acute | 1 | 2004 | 3610 | 0.020 |
Why?
|
| Poisson Distribution | 1 | 2009 | 504 | 0.020 |
Why?
|
| Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization | 1 | 2010 | 502 | 0.020 |
Why?
|
| Disease Management | 1 | 2019 | 2507 | 0.020 |
Why?
|
| Polymerase Chain Reaction | 2 | 2008 | 6067 | 0.020 |
Why?
|
| Pain | 1 | 2023 | 5072 | 0.020 |
Why?
|
| Mental Health Services | 1 | 2019 | 1716 | 0.020 |
Why?
|
| Erectile Dysfunction | 1 | 2011 | 444 | 0.020 |
Why?
|
| Lymph Node Excision | 1 | 2014 | 1270 | 0.020 |
Why?
|
| Propionates | 1 | 2008 | 181 | 0.020 |
Why?
|
| Cell Line, Transformed | 1 | 2008 | 864 | 0.020 |
Why?
|
| Blood Transfusion | 1 | 2014 | 1303 | 0.020 |
Why?
|
| Phosphoproteins | 1 | 2016 | 2444 | 0.020 |
Why?
|
| Hospitalization | 2 | 2010 | 10707 | 0.020 |
Why?
|
| Cell Nucleus | 1 | 2016 | 2881 | 0.020 |
Why?
|
| Health Policy | 1 | 2019 | 2679 | 0.020 |
Why?
|
| Public Health | 1 | 2020 | 2672 | 0.020 |
Why?
|
| Methionine | 1 | 2009 | 570 | 0.020 |
Why?
|
| Bone and Bones | 1 | 2017 | 2568 | 0.020 |
Why?
|
| Intensive Care Units | 1 | 2020 | 3744 | 0.020 |
Why?
|
| Incidental Findings | 1 | 2011 | 698 | 0.020 |
Why?
|
| Insulin Receptor Substrate Proteins | 1 | 2008 | 557 | 0.020 |
Why?
|
| Cell Membrane | 1 | 2016 | 3661 | 0.020 |
Why?
|
| Enhancer Elements, Genetic | 1 | 2013 | 1360 | 0.020 |
Why?
|
| Calcifediol | 1 | 2007 | 160 | 0.020 |
Why?
|
| AMP-Activated Protein Kinases | 1 | 2009 | 597 | 0.020 |
Why?
|
| Glucocorticoids | 1 | 2015 | 2159 | 0.020 |
Why?
|
| Sensitivity and Specificity | 2 | 2013 | 14675 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2017 | 5250 | 0.020 |
Why?
|
| Carcinoma, Squamous Cell | 1 | 2001 | 4021 | 0.020 |
Why?
|
| Drug Resistance, Neoplasm | 2 | 2011 | 5301 | 0.020 |
Why?
|
| Mice, Inbred C57BL | 1 | 2024 | 22128 | 0.020 |
Why?
|
| Immunoblotting | 1 | 2009 | 1644 | 0.020 |
Why?
|
| Bone Morphogenetic Proteins | 1 | 2011 | 840 | 0.020 |
Why?
|
| Calcitriol | 1 | 2007 | 295 | 0.020 |
Why?
|
| Chromatin Immunoprecipitation | 1 | 2008 | 848 | 0.020 |
Why?
|
| Maternal-Fetal Exchange | 1 | 2007 | 461 | 0.020 |
Why?
|
| Proteasome Endopeptidase Complex | 1 | 2011 | 1318 | 0.020 |
Why?
|
| Cross-Sectional Studies | 2 | 2019 | 26072 | 0.020 |
Why?
|
| Hematologic Neoplasms | 1 | 2017 | 1895 | 0.020 |
Why?
|
| DNA, Complementary | 1 | 2008 | 1989 | 0.010 |
Why?
|
| Drug Prescriptions | 1 | 2014 | 1668 | 0.010 |
Why?
|
| Tooth, Deciduous | 1 | 2005 | 76 | 0.010 |
Why?
|
| Pantothenic Acid | 1 | 2004 | 17 | 0.010 |
Why?
|
| Gene Expression Regulation, Enzymologic | 1 | 2009 | 1168 | 0.010 |
Why?
|
| Phenols | 1 | 2008 | 517 | 0.010 |
Why?
|
| Receptors, Progesterone | 1 | 2009 | 1129 | 0.010 |
Why?
|
| Cell Adhesion | 1 | 2010 | 3091 | 0.010 |
Why?
|
| Time | 1 | 2006 | 545 | 0.010 |
Why?
|
| Combined Modality Therapy | 1 | 2016 | 8519 | 0.010 |
Why?
|
| Costs and Cost Analysis | 1 | 2009 | 1664 | 0.010 |
Why?
|
| Placentation | 1 | 2004 | 78 | 0.010 |
Why?
|
| Fathers | 1 | 2006 | 375 | 0.010 |
Why?
|
| Maternal Welfare | 1 | 2004 | 112 | 0.010 |
Why?
|
| Attitude to Death | 1 | 2006 | 400 | 0.010 |
Why?
|
| Sigmoidoscopy | 1 | 2004 | 151 | 0.010 |
Why?
|
| Brain Neoplasms | 1 | 2004 | 9025 | 0.010 |
Why?
|
| Clinical Competence | 1 | 2019 | 4788 | 0.010 |
Why?
|
| Cell Line | 1 | 2017 | 15545 | 0.010 |
Why?
|
| Transforming Growth Factor beta | 1 | 2011 | 1963 | 0.010 |
Why?
|
| Morbidity | 1 | 2008 | 1751 | 0.010 |
Why?
|
| Quality-Adjusted Life Years | 1 | 2009 | 1723 | 0.010 |
Why?
|
| Gene Silencing | 1 | 2009 | 1495 | 0.010 |
Why?
|
| Gene Expression Regulation | 1 | 2020 | 11855 | 0.010 |
Why?
|
| Gene Expression | 1 | 2014 | 7571 | 0.010 |
Why?
|
| Protein Kinase Inhibitors | 1 | 2018 | 5665 | 0.010 |
Why?
|
| Parent-Child Relations | 1 | 2006 | 762 | 0.010 |
Why?
|
| Medicare | 1 | 2019 | 6774 | 0.010 |
Why?
|
| Health Care Rationing | 1 | 2005 | 435 | 0.010 |
Why?
|
| Pharyngeal Neoplasms | 1 | 2001 | 113 | 0.010 |
Why?
|
| Sexual Behavior | 2 | 2001 | 2189 | 0.010 |
Why?
|
| Receptors, Estrogen | 1 | 2009 | 2208 | 0.010 |
Why?
|
| Transplantation, Heterologous | 1 | 2009 | 2381 | 0.010 |
Why?
|
| Blotting, Western | 1 | 2008 | 5032 | 0.010 |
Why?
|
| Nutrition Assessment | 1 | 2004 | 727 | 0.010 |
Why?
|
| Sodium, Dietary | 1 | 2004 | 425 | 0.010 |
Why?
|
| Length of Stay | 1 | 2014 | 6417 | 0.010 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2012 | 10756 | 0.010 |
Why?
|
| Nausea | 1 | 2003 | 678 | 0.010 |
Why?
|
| Electronic Health Records | 1 | 2017 | 4822 | 0.010 |
Why?
|
| RNA, Small Interfering | 1 | 2009 | 3412 | 0.010 |
Why?
|
| Tongue Neoplasms | 1 | 2001 | 183 | 0.010 |
Why?
|
| Vomiting | 1 | 2003 | 650 | 0.010 |
Why?
|
| Alzheimer Disease | 1 | 2001 | 8606 | 0.010 |
Why?
|
| Mandatory Reporting | 1 | 2000 | 123 | 0.010 |
Why?
|
| Methoxamine | 1 | 1979 | 45 | 0.010 |
Why?
|
| Phenoxybenzamine | 1 | 1979 | 53 | 0.010 |
Why?
|
| Phentolamine | 1 | 1979 | 102 | 0.010 |
Why?
|
| Genomics | 1 | 2015 | 5829 | 0.010 |
Why?
|
| Dietary Carbohydrates | 1 | 2004 | 891 | 0.010 |
Why?
|
| Decision Making | 1 | 2013 | 3931 | 0.010 |
Why?
|
| Mental Disorders | 1 | 2019 | 6823 | 0.010 |
Why?
|
| Flow Cytometry | 1 | 2009 | 5871 | 0.010 |
Why?
|
| Pregnancy Rate | 1 | 2001 | 648 | 0.010 |
Why?
|
| Cell Survival | 1 | 2008 | 5778 | 0.010 |
Why?
|
| Head | 1 | 2004 | 922 | 0.010 |
Why?
|
| Genes, ras | 1 | 2000 | 654 | 0.010 |
Why?
|
| Laryngeal Neoplasms | 1 | 2001 | 514 | 0.010 |
Why?
|
| Pyrazoles | 1 | 2008 | 2010 | 0.010 |
Why?
|
| Base Sequence | 1 | 2008 | 12404 | 0.010 |
Why?
|
| Medical Records | 1 | 2003 | 1409 | 0.010 |
Why?
|
| Carrier State | 1 | 2000 | 522 | 0.010 |
Why?
|
| Norepinephrine | 1 | 1979 | 897 | 0.010 |
Why?
|
| Program Evaluation | 1 | 2005 | 2489 | 0.010 |
Why?
|
| Cells, Cultured | 1 | 2011 | 18927 | 0.010 |
Why?
|
| Mothers | 1 | 2006 | 2193 | 0.010 |
Why?
|
| Anxiety | 1 | 2010 | 4569 | 0.010 |
Why?
|
| HIV Infections | 1 | 2001 | 17348 | 0.010 |
Why?
|
| Communicable Disease Control | 1 | 2001 | 846 | 0.010 |
Why?
|
| Hepatitis B | 1 | 2000 | 703 | 0.010 |
Why?
|
| MicroRNAs | 1 | 2009 | 3758 | 0.010 |
Why?
|
| Rabbits | 1 | 1979 | 4750 | 0.010 |
Why?
|
| Suicide, Attempted | 1 | 2001 | 1402 | 0.010 |
Why?
|
| Communication | 1 | 2006 | 3872 | 0.010 |
Why?
|
| Palliative Care | 1 | 2006 | 3599 | 0.010 |
Why?
|
| Kinetics | 1 | 1979 | 6312 | 0.010 |
Why?
|
| Esophageal Neoplasms | 1 | 2001 | 1658 | 0.010 |
Why?
|
| Women's Health | 1 | 2000 | 2070 | 0.010 |
Why?
|
| Binding Sites | 1 | 1979 | 5988 | 0.010 |
Why?
|
| Weight Loss | 1 | 2001 | 2680 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2009 | 18222 | 0.010 |
Why?
|
| Hepatitis C | 1 | 2000 | 1579 | 0.010 |
Why?
|
| Methyldopa | 1 | 1980 | 18 | 0.000 |
Why?
|